Find a Clinical Trial

Showing 1 - 5 out of 5

Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus

2-Part Seamless Part A (Phase 2)/Part B (Phase 3) Randomized,
Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the
Efficacy and Safety of BIIB059 in Participants with Active Subacute
Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus
Erythematosus with or without Systemic Manifestations and Refractory
and/or Intolerant to Antimalarial Therapy (AMETHYST)

Cutaneous disorders

All genders

18+

Recruiting now

Department of Dermatology

Tufts Medical Center

Learn more

Psoriasis

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

All genders

18+

Recruiting now

Department of Dermatology

Tufts Medical Center

Learn more

Atopic Dermatitis (Eczema)

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and
older with moderate-to-severe atopic dermatitis (eczema).

Atopic dermatitis

All genders

12-17

Recruiting now

Department of Dermatology

Tufts Medical Center

Learn more

Clinical Outcomes Of Primary Sclerosing Cholangitis In North America

Sclerosing cholangitis

All genders

No minimum age

Recruiting now

Department of Medicine, Division of Gastroenterology + Hepatology

Tufts Medical Center

Learn more

Exploring the Role of the Mineralocorticoid Receptor in Human Vascular Disease

Vascular diseases

All genders

18+

Recruiting now

Department of Surgery, Division of Vascular Surgery

Tufts Medical Center

Learn more

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and
older with moderate-to-severe atopic dermatitis (eczema).

Clinical Outcomes Of Primary Sclerosing Cholangitis In North America

Exploring the Role of the Mineralocorticoid Receptor in Human Vascular Disease

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis (eczema).

Clinical Outcomes Of Primary Sclerosing Cholangitis In North America

Exploring the Role of the Mineralocorticoid Receptor in Human Vascular Disease

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and
older with moderate-to-severe atopic dermatitis (eczema).